Osteopontin in cardiovascular disease: A potential therapeutic target

Cardiology in Review

Volumn 18, Issue 3, 2010, Pages 125-131

  Waller, Alfonso H ^a   Sanchez Ross, Monica ^a   Kaluski, Edo ^a   Klapholz, Marc ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Calcification; Heart failure; Myocardial infarction; Myocardial remodeling; Osteopontin; Valvular disease

Indexed keywords

BIOLOGICAL MARKER; OSTEOPONTIN;

CARDIOVASCULAR DISEASE; CELL TYPE; HEART FAILURE; HEART INFARCTION; HUMAN; MEDIATOR; NONHUMAN; PROTEIN EXPRESSION; REVIEW; VALVULAR HEART DISEASE; VASCULAR DISEASE;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HEART FAILURE; HEART VALVE DISEASES; HUMANS; MYOCARDIAL INFARCTION; OSTEOPONTIN;

EID: 77951483204     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181cfb646     Document Type: Review

References (68)

1. Franzen A, Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J. 1985;232:715-724.
2. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA. 1986;83:8819-8823.
3. Fisher LW, Torchia DA, Fohr B, et al. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun. 2001;280:460-465.
4. Rodrigues LR, Teixeira JA, Schmitt FL, et al. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:1087-1097.
5. O'Regan A, Berman JS. Osteopontin: A key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol. 2000;81:373-390.
6. Young MF, Kerr JM, Termine JD, et al. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics. 1990;7:491-502.
7. Miyazaki Y, Setoguchi M, Yoshida S, et al. The mouse osteopontin gene: expression in monocytic lineages and complete nucleotide sequence. J Biol Chem. 1990;265:14432-14438.
8. Liaw L, Lindner V, Schwartz SM, et al. Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ Res. 1995;77: 665-672.
9. Schnapp LM, Hatch N, Ramos DM, et al. The human integrin alpha 8 beta 1 functions as a receptor for tenascin, fibronectin, and vitronectin. J Biol Chem. 1995;270:23196-23202.
10. Smith LL, Cheung HK, Ling LE, et al. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J Biol Chem. 1996;271:28485-28491.
11. Yokosaki Y, Matsuura N, Sasaki T, et al. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved aminoterminal fragment of osteopontin. J Biol Chem. 1999;274:36328-36334.
12. Bayless KJ, Davis GE. Identification of dual alpha 4beta1 integrin binding sites within a 38 amino acid domain in the N-terminal thrombin fragment of human osteopontin. J Biol Chem. 2001;276:13483-13489.
13. Bayless KJ, Meininger GA, Scholtz JM, et al. Osteopontin is a ligand for the alpha4beta1 integrin. J Cell Sci. 1998;111(pt 9):1165-1174.
14. Green PM, Ludbrook SB, Miller DD, et al. Structural elements of the osteopontin SVVYGLR motif important for the interaction with alpha(4) integrins. FEBS Lett. 2001;503:75-79.
15. Senger DR, Perruzzi CA, Papadopoulos-Sergiou A, et al. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell. 1994;5:565-574.
16. Scatena M, Liaw L, Giachelli CM. Osteopontin: A multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2302-2309.
17. Weber GF, Ashkar S, Glimcher MJ, et al. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science. 1996;271:509-512.
18. Katagiri YU, Sleeman J, Fujii H, et al. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res. 1999;59:219-226.
19. Chellaiah MA, Kizer N, Biswas R, et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell. 2003;14:173-189.
20. Xie Z, Pimental DR, Lohan S, et al. Regulation of angiotensin II-stimulated osteopontin expression in cardiac microvascular endothelial cells: role of p42/44 mitogen-activated protein kinase and reactive oxygen species. J Cell Physiol. 2001;188:132-138.
21. Giachelli C, Bae N, Lombardi D, et al. Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR). Biochem Biophys Res Commun. 1991;177:867-873.
22. Giachelli CM, Bae N, Almeida M, et al. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 1993;92:1686-1696.
23. Senger DR, Ledbetter SR, Claffey KP, et al. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol. 1996;149:293-305.
24. Nugent MA, Iozzo RV. Fibroblast growth factor-2. Int J Biochem Cell Biol. 2000;32:115-120.
25. Leali D, Dell'Era P, Stabile H, et al. Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol. 2003;171:1085-1093.
26. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science. 2000;287: 860-864.
27. Giachelli CM, Lombardi D, Johnson RJ, et al. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol. 1998;152:353-358.
28. Wang X, Louden C, Ohlstein EH, et al. Osteopontin expression in plateletderived growth factor-stimulated vascular smooth muscle cells and carotid artery after balloon angioplasty. Arterioscler Thromb Vasc Biol. 1996;16: 1365-1372. (Pubitemid 26378227)
29. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605-1612.
30. Bruemmer D, Collins AR, Noh G, et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest. 2003;112:1318-1331.
31. Beadenkopf WG, Daoud AS, Love BM. Calcification in the coronary arteries and its relationship to arteriosclerosis and myocardial infarction. Am J Roentgenol Radium Ther Nucl Med. 1964;92:865-871.
32. Fitzpatrick LA, Severson A, Edwards WD, et al. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. J Clin Invest. 1994;94:1597-1604.
33. Rajamannan NM, Subramaniam M, Rickard D, et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003; 107:2181-2184.
34. Srivatsa SS, Harrity PJ, Maercklein PB, et al. Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves. J Clin Invest. 1997;99:996-1009.
35. O'Brien KD, Kuusisto J, Reichenbach DD, et al. Osteopontin is expressed in human aortic valvular lesions. Circulation. 1995;92:2163-2168.
36. Steitz SA, Speer MY, McKee MD, et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol. 2002;161:2035-2046.
37. Singh K, Deonarine D, Shanmugam V, et al. Calcium-binding properties of osteopontin derived from non-osteogenic sources. J Biochem. 1993;114:702-707.
38. Ikeda T, Shirasawa T, Esaki Y, et al. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest. 1993;92:2814-2820.
39. Ohmori R, Momiyama Y, Taniguchi H, et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis. 2003;170:333-337.
40. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics- 2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69-e171.
41. Murry CE, Giachelli CM, Schwartz SM, et al. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol. 1994;145:1450-1462.
42. Komatsubara I, Murakami T, Kusachi S, et al. Spatially and temporally different expression of osteonectin and osteopontin in the infarct zone of experimentally induced myocardial infarction in rats. Cardiovasc Pathol. 2003;12:186-194.
43. Suezawa C, Kusachi S, Murakami T, et al. Time-dependent changes in plasma osteopontin levels in patients with anterior-wall acute myocardial infarction after successful reperfusion: correlation with left-ventricular volume and function. J Lab Clin Med. 2005;145:33-40.
44. Coskun S, Atalar E, Ozturk E, et al. Plasma osteopontin levels are elevated in non-ST-segment elevation acute coronary syndromes. J Natl Med Assoc. 2006;98:1746-1750.
45. Tamura A, Shingai M, Aso N, et al. Osteopontin is released from the heart into the coronary circulation in patients with a previous anterior wall myocardial infarction. Circ J. 2003;67:742-744.
46. Kato R, Momiyama Y, Ohmori R, et al. High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. Arterioscler Thromb Vasc Biol. 2006;26:e1-e2.
47. Cohn JN, Ferrari R, Sharpe N; behalf of an International Forum on Cardiac Remodeling. Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35:569-582.
48. Trueblood NA, Xie Z, Communal C, et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res. 2001;88:1080-1087.
49. Takano H, Hasegawa H, Nagai T, et al. Implication of cardiac remodeling in heart failure: mechanisms and therapeutic strategies. Intern Med. 2003;42: 465-469.
50. Singh K, Balligand JL, Fischer TA, et al. Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells: role in regulation of inducible nitric oxide synthase. J Biol Chem. 1995;270:28471-28478.
51. Hou J, Kato H, Cohen RA, et al. Angiotensin II-induced cardiac fibrosis in the rat is increased by chronic inhibition of nitric oxide synthase. J Clin Invest. 1995;96:2469-2477.
52. Pfeffer JM, Pfeffer MA, Mirsky I, et al. Prevention of the development of heart failure and the regression of cardiac hypertrophy by captopril in the spontaneously hypertensive rat. Eur Heart J. 1983;4(suppl A):143-148.
53. Williams EB, Halpert I, Wickline S, et al. Osteopontin expression is increased in the heritable cardiomyopathy of Syrian hamsters. Circulation. 1995;92: 705-709.
54. Graf K, Do YS, Ashizawa N, et al. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation. 1997;96:3063-3071.
55. Ashizawa N, Graf K, Do YS, et al. Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. J Clin Invest. 1996;98:2218-2227.
56. Singh K, Sirokman G, Communal C, et al. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension. 1999;33:663-670.
57. Xie Z, Singh M, Singh K. ERK1/2 and JNKs, but not p38 kinase, are involved in reactive oxygen species-mediated induction of osteopontin gene expression by angiotensin II and interleukin-1beta in adult rat cardiac fibroblasts. J Cell Physiol. 2004;198:399-407.
58. Kawano H, Cody RJ, Graf K, et al. Angiotensin II enhances integrin and alpha-actinin expression in adult rat cardiac fibroblasts. Hypertension. 2000; 35:273-279. (Pubitemid 30054185)
59. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail. 1996;2:47-54.
60. Rocha R, Martin-Berger CL, Yang P, et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology. 2002;143:4828-4836.
61. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002;283:H1802-H1810.
62. Matsui Y, Jia N, Okamoto H, et al. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension. 2004;43:1195-1201.
63. Sam F, Xie Z, Ooi H, et al. Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. Am J Hypertens. 2004;17:188-193.
64. Collins AR, Schnee J, Wang W, et al. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. J Am Coll Cardiol. 2004;43: 1698-1705.
65. Stawowy P, Blaschke F, Pfautsch P, et al. Increased myocardial expression of osteopontin in patients with advanced heart failure. Eur J Heart Fail. 2002;4:139-146.
66. Satoh M, Nakamura M, Akatsu T, et al. Myocardial osteopontin expression is associated with collagen fibrillogenesis in human dilated cardiomyopathy. Eur J Heart Fail. 2005;7:755-762.
67. Arnlov J, Evans JC, Benjamin EJ, et al. Clinical and echocardiographic correlates of plasma osteopontin in the community: the Framingham heart study. Heart. 2006;92:1514-1515.
68. Soejima H, Irie A, Fukunaga T, et al. Osteopontin expression of circulating T cells and plasma osteopontin levels are increased in relation to severity of heart failure. Circ J. 2007;71:1879-1884.